Tenapanor reimbursement ratio and patient cost analysis

Tenapanor (tenapanor) is a new oral drug used to treat chronic kidney disease with hyperphosphatemia or constipation-predominant irritable bowel syndrome. Its mechanism of action is mainly by inhibiting intestinal sodium- hydrogen exchange proteins and reducing the absorption of sodium and phosphorus, thereby improving blood phosphorus levels or promoting intestinal defecation function. The drug is clinically considered a targeted therapy for specific patient groups.

In the domestic market, Tenapano has been officially launched and is included in medical insurance. Therefore, patients need to purchase it at their own expense when using it in the country, and the specific price has not yet been announced. Since the drug is a newly launched drug, its cost and purchase channels may differ in different hospitals and pharmacies. Patients need to consult the medical institution or pharmacy in advance to learn how to obtain it.

In overseas markets, Tenapano's original drug is more expensive, with each box selling for more than 3,000 U.S. dollars. It is mainly targeted at markets such as the United States and Europe. For patients, overseas purchase costs are high, and issues such as transportation, storage, and usage regulations must also be considered. Therefore, they are usually obtained through local medical institutions or authorized pharmacies to ensure that the source of drugs is legal and the quality is reliable.

In addition, imitation versions of Tenapano have appeared in overseas markets, such as 30mg*14 tablets produced by Lucius in Laos, priced at approximately 600 RMB per box. The ingredients of this generic drug are basically the same as those of the original drug, but a doctor still needs to evaluate the suitability and dosage regimen before use.

Reference:https://en.wikipedia.org/wiki/Tenapanor